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A breast-risk score, published in 2016, was developed in white-American women using 92 genetic 
variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score 
in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, 
modifiable and non-modifiable risk factor scores were estimated via logistic regression. SNPs without 
available genotyping were simulated as in the aforementioned 2016 study. The full model score was 
obtained by combining GRS92, modifiable and non-modifiable risk factor scores. Score performances 
were tested via the area under the ROC curve (AUROC), net reclassification index (NRI) and integrated 
discrimination improvement (IDI). Compared with non-modifiable and modifiable factor scores, 
GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and 0.5214, respectively). Adding 
the non-modifiable factor score to GRS92 improved patient classification by 23.6% (NRI = 0.236), 
while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. 
A simulation study showed the ability of the full model for identifying women at high risk for breast 
cancer. In conclusion, a model combining genetic and risk factors can be used for stratifying women 
by their breast cancer risk, which can be applied to individualizing genetic counseling and screening 
recommendations.
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Breast cancer is the most frequent type of cancer in women worldwide and a main cause of cancer death in devel-
oped countries1. Epidemiological research has led to the identification of several risk factors (age at menarche, 
parity, age at first full-term pregnancy, age at menopause), most of them associated with estrogen production2,3. 
A number of risk factors are related with lifestyle (tobacco smoking, alcohol consumption, overweight or obe-
sity), although their importance seems to be smaller than the estrogen/reproductive life-associated risk factors4. 
Known risk factors can only explain about 40% of breast cancer risk.
A few highly penetrant genetic variants, like those in BRCA1 and BRCA2 genes, have been proved to increase 
breast cancer risk5,6; although their low prevalence hardly allows them to explain around 5% cases of breast can-
cer7, carrying any of these variants puts women in such a high risk that screening practices have been adapted 
in carrier women and even oophorectomy or early mastectomy can be considered in some cases in the absence 
of breast cancer diagnosis8. With the advent of next generation sequencing techniques, an increasing number of 
low-penetrant genetic variants are being identified as related to breast cancer7 and some polygenic tests have been 
marketed intending to identify women at high risk of breast cancer, although their clinical relevance is uncertain.
In this way, Maas et al. presented a breast cancer risk model among white women in the United States, which 
included modifiable and non-modifiable risk factors, as well as a genetic risk score with information from 92 
genetic variants9. The goal of this article is to validate Maas et al.’s model in a Spanish case-control study.
Methods
Study design and population. The Multi Case-Control (MCC-Spain) study is a population-based 
case-control study of common tumors in Spain and has been described elsewhere. It has been carried out in 23 
hospitals and primary care centers in 12 Spanish provinces and assesses five types of cancer (colorectal, breast, 
stomach, prostate and chronic lymphocytic leukemia) using the same series of population controls for all cases10. 
Cases and controls were recruited between September 1st, 2008 and December 31st, 2013.
We included 1,732 incident cases of breast cancer in women and 1,910 controls in ten participating centers 
(Asturias, Barcelona, Cantabria, Girona, Gipuzkoa, Huelva, León, Madrid, Navarra and Valencia). Cases were 
aged 20–85 and with a new pathology-confirmed diagnosis of breast cancer living in the catchment area of each 
hospital at least 6 months prior to the diagnosis. Controls were women without history of breast cancer living 
in the same catchment area as cases; they were randomly selected from the rosters of General Practitioners at 
the Primary Health Centers. Controls were frequency-matched to cases by 5-year age groups and study area. 
Response rates were 72% among cases and 52% among controls.
The study was carried out according to Spanish laws on biomedical research. All procedures were performed 
with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments.
The Ethics Committees of the participating hospitals (Ethical Committee of Clinical Research of Barcelona, 
Cantabria, Girona, Gipuzkoa, Huelva, León, Principado de Asturias, Madrid, Navarra and Valencia) approved the 
study protocols, and participants provided written informed consent at the time of enrollment.
Data collection. Participants were interviewed face-to-face by trained interviewers with a comprehensive 
epidemiological questionnaire that assessed socio-demographic information, personal and family history of can-
cer, anthropometric data, alcohol consumption, smoking habits, reproductive and medical history, and family 
history. Participant’s weight was recorded by self-report, as estimated one year before diagnosis for cases and for 
controls. Body mass index (BMI) was estimated from self-reported weight and height one year before the diag-
nosis for cases and one year prior to the interview for controls. Blood samples were obtained following the study 
protocol. Elapsed time between breast cancer diagnosis and interview was 117 days on average.
Genotyping. The genotyping was performed for 1,138 cases and 1,239 controls using the Infinium Human 
Exome BeadChip (Illumina, San Diego, USA) that includes >200,000 coding markers plus 5,000 additional cus-
tom SNPs selected from previous GWAS or in genes of interest.
Genetic score. In order to construct the genetic score, we consider two SNP sets. The first set included 24 
SNPs identified from Breast and Prostate Cancer Cohort Consortium (BPC3 study) (Supplementary Table 1)11–13. 
17 of them were included in the performed genotyping; the remaining 7 (rs10069690, rs10941679, rs17530068, 
rs1250003, rs10483813, rs6504950 and rs2284378) were imputed using SNPSTATs14,15. The 24-SNP genetic score 
(GRS24) was estimated by the addition of the beta coefficients as obtained in BPC3 study13. Barrdahl et al.13 con-
sidered rs10483813 as surrogate for rs999737 as they are in strong linkage disequilibrium; therefore, we excluded 
rs10483813 from GRS24 in order to do not double the weight of this locus. As genotyping was not available for 
594 cases and 671 controls, we simulated GRS24 in them using the method suggested by Chatterjee et al.16 as 
explained in the following paragraph.
The second set of SNPs included 68 identified in Breast Cancer Association Consortium (BCAC) and 
Collaborative Oncological Gene-Environment Study (COGS) (Supplementary Table 1). They were not included 
in the genotyping, so the 68-SNP genetic score (GRS68) was simulated with the Chatterjee et al. method16, as 
performed by Maas et al.9 when developing the score we are trying to validate. In brief, GRS68 was obtained 
using the reported beta coefficients (=log odds ratios) and conditional on case-control status and family history 
of breast cancer as:
µ σ| = = −~P GRS D d Family H h N( 68 , ) ( , ) (1)i GRS 68
2
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where σ σ= × + × ×d hGRS GRS68
2 1
2 68
2 , σ β= ∑ −ˆ f f2 (1 )GRS k k k k68
2 2 , subindex i refers to the participants included 
in the study and k refers to the SNPs included in the model, β̂k are the estimates of the log odds ratios, and fk are 
the risk allele frequencies. β̂k and fk were obtained from the BCAC17,18.
Finally, a 92-SNP genetic score (GRS92) was obtained by adding GRS24 plus GRS68. Supplementary Table 2 
displays R2 as a measure of linkage disequilibrium between the SNPs located in the same chromosome, according 
to the European population in the 1000 Genome Project and were obtained from https://analysistools.nci.nih.
gov/LDlink/?tab=home.
Modifiable risk factor score. The modifiable risk factor score (MRFS) included BMI, menopausal hormone ther-
apy, level of alcohol consumption, and smoking status. Alcohol use and BMI were categorized as in Maas et al.9  
(Supplementary Table 3). In order to build MRFS, we carried out a multivariate logistic regression analysis includ-
ing the above indicated modifiable risk factors. Then, MRFS was obtained by adding the estimated beta coeffi-
cients of the above indicated risk factors, every beta being adjusted for each other factor.
Non-modifiable risk factor score. The non-modifiable risk factor score (NMRFS) included family history, age at 
first birth, parity, age at menarche, height, menopausal status, and age at menopause. According to Maas et al.9, 
age at first birth and parity were considered “non-modifiable” as it is unlikely that women modify these factors 
because of their breast cancer risk. Age at menarche, age at first birth, height and age at menopause were catego-
rized as in Maas et al.9 (Supplementary Table 3). NMRFS was built in the same way that MRFS.
Full model. The full model (FM) was obtained as the addition of GRS92 + MRFS + NMRFS.
Statistical analysis. The independence among the scores was tested using the Pearson correlation coeffi-
cient. Differences in scoring between cases and controls were tested with the Student-t test. In order to analyze the 
association among scores and breast cancer, scores were categorized into deciles; then, a logistic regression model 
was constructed for each score, with decile 1 as reference. ROC curves and their area under the curve (AUROC) 
were obtained for each logistic model.
For analyzing whether a score adds or not to the predictive ability of another score, we estimated the net 
reclassification improvement (NRI), the integrated discrimination improvement (IMI) and the improvement in 
the AUROC. The goal for a score is to classify breast cancer cases and controls adequately; when two scores -say 
GRS24 and GRS92- are compared, GRS92 would classify some cases better than GRS24 and some others worse; 
likewise, GRS92 would classify some controls better and some others worse. NRI19 is the net sum of classifying 





NRI P cases classified better with GRS92
P cases classified worse with GRS92
P controls classified better with GRS92





It is noteworthy that NRI can only be applied when both scores are nested one in each other, as it is the case 
between GRS24 and GRS92, because GRS92 equals GRS24 plus GRS68. In this article, we use the continuous 
version of NRI20.
While NRI measures the improvement in classification, IMI estimates the improvement in predicted proba-
bility. A better score is expected to predict higher probabilities in cases and lower probabilities in controls than a 





IMI P Breast cancer estimated with GRS92 in cases
P Breast cancer estimated with GRS24 in cases
P Breast cancer estimated with GRS24 in controls





Finally, in order to explore the ability of the scores to identify women at high risk of breast cancer, we sim-
ulated the expected breast cancer incidence rate according to their scoring in GRS92, NMRFS, MRFS and full 
model. For instance, the simulation for GRS92 was built as follows: First, a logistic regression model was esti-
mated using GRS92 as regressor and breast cancer as event, obtaining a β coefficient (=log (OR)). Second, inci-
dence rates by 5-year age groups were obtained from Globocan1,21; these rates were attributed to patients with the 
average GRS92. Lastly, incidence rates for each patients were simulated by multiplying the average age-specific 
incidence rate times exp[β*(GRS92 – average GRS92)]. Similar simulations were performed for NMRFS, MRFS 
and full model. All statistical analyses were performed with the software Stata 14/SE (Stata Co., College Station, 
TX, US).
Results
1,732 breast cancer cases and 1,910 controls were included in the analysis; their main characteristics are reported 
in Supplementary Table 4. Compared to controls, cases were 2.6 younger in average, they have about twice the 
probability of having a first degree relative affected of breast cancer, their age at menarche was a bit earlier and 
their age at menopause was later, and they have less children. There were no differences in height, BMI, alcohol 
consumption and age at first delivery. The distributions of genetic risk scores with 24 [GRS24], 68 [GRS68] and 
92 [GRS92] SNPs; modifiable risk factor score [MRFS]; nonmodifiable risk factor score [NMRFS], and full model 
www.nature.com/scientificreports/
4SCIENTIFIC RePoRTS |  (2018) 8:3036  | DOI:10.1038/s41598-018-20832-0
[FM] are reported in Fig. 1. All scores show a high degree of overlapping between cases and controls, being MRFS 
the less discriminant score. BC cases scored higher than controls in each risk score (Supplementary Table 5). 
GRS92, MRFS and NMRFS were not linearly dependent from each other as their Pearson correlation coefficient 
was <0.06 (Supplementary Table 6).
The association between GRS92 and breast cancer is displayed in Table 1, where the odds ratio increased decile 
by decile; patients in the 10th decile had 3.8 the odds of breast cancer than patients in the first decile and double 
the odds than patients around the median of GRS92 distribution (i.e.: patients in 5th or 6th deciles). The area under 
the ROC curve (AUROC) was 0.6195; GRS24 and GRS68 -the two components of GRS92- had smaller prediction 
ability, with AUROC being equal to 0.5676 and 0.5936, respectively (Supplementary Figure 1).
Nonmodifiable risk factors show a dose-response relationship with breast cancer from the fifth decile on; the 
first four deciles, however, do not exhibit any increase in risk (Table 1). The AUROC was 0.5885 (Supplementary 
Figure 1).
Figure 1. Kernel density plots on distribution of genetic and risk factor scores in breast cancer cases (red line) 
and controls (blue line).
Decile GRS92 NMRFS MRFS Full model
1 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
2 1.27 (0.90–1.78) 0.90 (0.67–1.22) 1.03 (0.79–1.34) 1.82 (1.29–2.56)
3 1.22 (0.87–1.71) 1.18 (0.88–1.58) 1.05 (0.76–1.46) 1.54 (1.09–2.17)
4 1.79 (1.28–2.49) 1.02 (0.75–1.37) 1.16 (0.88–1.53) 2.56 (1.83–3.60)
5 2.00 (1.43–2.78) 1.36 (1.01–1.83) 0.83 (0.64–1.08) 2.12 (1.51–2.98)
6 2.17 (1.56–3.03) 1.63 (1.21–2.20) 1.33 (0.96–1.84) 2.08 (1.48–2.92)
7 2.35 (1.69–3.27) 1.59 (1.18–2.14) 1.11 (0.85–1.45) 2.34 (1.67–3.29)
8 2.54 (1.82–3.54) 2.00 (1.48–2.70) 1.06 (0.78–1.44) 3.28 (2.34–4.60)
9 3.82 (2.74–5.35) 2.03 (1.50–2.73) 1.14 (0.87–1.49) 4.45 (3.16–6.26)
10 3.80 (2.72–5.32) 2.43 (1.79–3.29) 1.46 (1.08–1.97) 5.70 (4.02–8.07)
Table 1. Relationship among breast cancer and different scores. Odds ratios per decile of each score. GRS92: 
Genetic Risk Score with 92 SNPs. NMRFS: Non-modifiable Risk Factor Score. MRFS: Modifiable Risk Factor 
Score.
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Modifiable risk factor score had little association with breast cancer (Table 1); only patients in the 10th decile 
had an odds ratio around 1.5 respect to patients in the first decile. Its ROC curve was hardly over the diagonal, 
displaying small discrimination power (AUROC = 0.5214) (Supplementary Figure 1).
The improvement in risk prediction when adding more component scores from GRS24 on was measured with 
three indicators: net reclassification index (NRI) (equation (2)), integrated discrimination improvement (IDI) 
(equation (3)) and improvement in AUROC, whose results are displayed in Table 2. Adding GRS68 to GRS24 
(i.e.: constructing GRS92) improved patient classification by 28.2% (NRI = 0.282) and the difference in the prob-
abilities of suffering breast cancer between cases and controls improved by 2.7% (IDI = 0.027). Adding NMRFS 
up to GRS92 still improved patient classification by 23.6%, in spite of moderate improvements in IDI (0.015) and 
AUROC (0.0141). Adding MRFS to GRS92, however, only scored 7.2% in NRI with marginal enhancements in 
IDI and AUROC. Being low the betterment of MRFS over GRS92, most of it seems to be redundant with NMRFS 
as adding MRFS to NMRFS hardly improved patient classification (NRI = 0.017), discrimination (IDI = 0.000) 
and AUROC (−0.0013).
The full model, thus, mainly reflects the combination of the genetic score GRS92 and the non-modifiable 
risk score (NMRFS). Its relationship with breast cancer stepped up by each decile (Table 1); the AUROC reached 
0.6244 (Supplementary Figure 1).
Figure 2 exhibits the expected breast cancer incidence rates by age, according to GRS92, NMRFS, MRFS and 
full model. Lines represent percentiles 1, 5, 10, 25, 50, 75, 90, 95 and 99 of each score distribution. Figure 2A–D 
are represented in the same Y scale in order to easily identify which models are more able to classify patients 
according to their risk: the more separated the lines are, the higher the model ability to classify patients. GRS92 







GRS24 GRS24 + GRS68 = GRS92 0.282 0.027 0.0484 <0.001
GRS92 GRS92 + NMRFS 0.236 0.015 0.0141 0.01
GRS92 GRS92 + MRFS 0.072 0.003 0.0024 0.37
NMRFS NMRFS + MRFS = RFS 0.017 0.000 −0.0013 0.18
Table 2. Improvement in risk prediction when adding more component scores. *p value for the improvement 
in AUROC. GRS24: Genetic Risk Score with 24 SNPs. GRS68: Genetic Risk Score with 68 SNPs. GRS92: Genetic 
Risk Score with 92 SNPs. NMRFS: Non-modifiable Risk Factor Score. MRFS: Modifiable Risk Factor Score. RFS: 
Risk Factor Score.
Figure 2. Projected breast-cancer incidence rate by age, according to the percentiles of the scores. (A) Genetic 
score; (B) Non-modifiable risk factors; (C) Modifiable risk factors; (D) Full model. In each graphic, lines from 
bottom to top represent percentiles 1, 5, 10, 25, 50, 75, 90, 95 and 99.
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(Fig. 2A), NMRFS (Fig. 2B) and especially full model (Fig. 2D) allowed for identifying patients in high risk of 
breast cancer.
Discussion
In this case-control study, we have found that a model for breast cancer risk stratification developed in white 
women in the United States9 similarly performs in the Spanish population.
Relative relevance of GRS, NMRFS, MRFS. According to our results, modifiable risk factors do not 
discriminate well between breast cases and controls, which questions our ability to implement breast cancer 
primary prevention policies. Of note, several modifiable factors (namely, alcohol consumption, BMI and tobacco 
smoking) have been identified as risk factors for many other frequent diseases (e.g.: cardiovascular diseases, 
lung cancer and other cancers); thus, general recommendations for moderating alcohol consumption, avoiding 
tobacco smoking and maintaining BMI in its optimal range are considered among the most important health 
promotion recommendations, despite we do not observe that these factors can discriminate between breast cases 
and controls.
Consequences for screening. The US Preventive Services Task Force recommends biennial breast cancer 
screening with mammography for all women aged 50 to 74 “who are not at high risk of breast cancer because of 
a known underlying genetic mutation”22. GRS92, NMRFS and full model, however, could be useful in stratifying 
women according to their breast cancer risk. Women scoring in the 10th decile in GRS92 or full model could have 
double the risk of women with the average scoring and four- to six-fold the risk of women in the first decile, which 
makes it sensible to use these scores for individualizing the breast cancer screening recommendations. Genetic 
risk is already being the basis for changing screening periodicity; for instance, women carrying mutations in the 
gene BRCA1 have about 4-fold the risk of the average women, which supports performing screen mammography 
every six months23 and could even sustain recommendations for oophorectomy and/or mastectomy on an indi-
vidual basis. In a similar way, a two-fold increase in risk over the average could lead to shorten the usual two-year 
interval for mammography in women scoring high in GRS92 or in the full model; alternatively, women scoring 
high in GRS92 or in the full model could benefit from initiating screening mammography before being 50; in 
this way, results from a simulation study24 suggest that women with two-fold to four-fold increased risk for breast 
cancer could be annually screened starting at age 40 with similar harm-to-benefit ratio than the biennial screen-
ing starting at age 50 for the average-risk women. Likewise, women in the first decile have about half the risk of 
the average women, which could induce to reconsider the balance of harms and benefits they have when being 
screened and, thus, to discuss the possibility of widening their mammography interval, delaying their starting age 
or even reconsidering the utility the screening program has for them.
Consequences for communicating risk. Genetic counseling has been available since testing for BRCA1 
and BRCA2 was developed about 20 years ago25. New sequencing technologies make polygenic panel tests accessi-
ble26,27; applying them to risk assessment would allow genetic counseling to go further than a few highly-penetrant 
variants, which opens new ways for advising women before breast cancer can develop. Moreover, genetic scores 
on breast cancer and non-modifiable risk factors seem to be independent from each other; according to our 
results, stratifying breast cancer risk combining both genetic score (GRS92) and non-modifiable risk factors 
(NMRFS) improves patient classification by 28%. From a woman’s point of view, it is of no relevance whether her 
[possible] breast cancer would be caused by a sum of genetic variant or non-modifiable risk factors or a combina-
tion of both; in this way, it could be time for moving from genetic counseling towards risk counseling, irrespective 
of the factors related to that risk. Maas et al.’s model9, which we have here validated in a Spanish population, could 
be a well-founded instrument for doing it.
Limitations. Our study has some limitations. First, genotyping was available only for 65% of our patients; 
therefore, GRS24 had to be imputed in the remaining 35%. In order to validate this imputation, we carried out 
a sensitivity analysis on the GRS24 – breast cancer relationship in participants with and without genotyping 
data (Supplementary Table 7); OR by deciles were very similar in both groups, reinforcing the way genotype 
was imputed. Genotyping of the SNPs included in GRS68, however, was not available at all, so GRS68 was com-
pletely imputed as it actually was in the paper were the score was developed9. Second, when constructing GRS92, 
rs10483813 was excluded because of its almost perfect correlation with rs999737; apart from it, only two other 
SNPs (rs6678914 and rs4245739) displayed R2 with each other greater than 0.3 (Supplementary Table 2), involv-
ing some degree of linkage disequilibrium; however, we consider that their correlation was not high enough to 
exclude one of them in spite of admitting some redundancy degree. Third, a main concern in our results was 
the weak breast cancer - modifiable risk factors association; of note, reproductive and lifestyle factors have been 
measured by self-reporting; in this way, data are exposed to recall bias. As breast cancer participants were aware 
of their condition, we cannot rule out that their reports could be more biased that those of controls; this could 
be especially considered when reporting unhealthy lifestyles such as alcohol consumption or tobacco smoking, 
eventually leading to downward OR estimations. On the other hand, hormone replacement therapy has been 
used for less than 10% Spanish women28, which makes it difficult to find a relevant impact on breast cancer risk. 
Fourth, we limited our analysis to validate Maas et al.’s model in our case-control study; therefore, we did not 
go further than their article13 in exploring interactions between genetic and non-genetic risk factors, which -on 
the other hand- could be limited given the sample size our study has. Fifth, other risk factor models for BC have 
been published; for instance, Rosner and Colditz developed29 and refined30 a cumulative risk model based on the 
Nurses’ Health Study. Rosner – Coldtiz model, however, does not include genetic variants, which is a main point 
in Maas et al.’s score; therefore, we have not conducted a specific comparison between them.
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In conclusion, when validating a breast cancer model, we have found that adding a non-modifiable risk factor 
score to a polygenic score can largely improve patient’s risk stratification. Its potential utilities would include 
risk-based screening programs or changes in genetic/risk counseling on breast cancer.
References
 1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 
136, E359–E386, https://doi.org/10.1002/ijc.29210 (2015).
 2. Golubnitschaja, O. et al. Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative 
questionnaires and recommendations for preventive measures. Tumour Biol. 37(10), 12941–12957 (2016).
 3. Lambertini, M. et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review 
and meta-analysis of epidemiological studies. Cancer Treatment Reviews 49, 65–76 (2016).
 4. Hankinson S., Tamimi R., Hunter D. Breast Cancer in Textbook of Cancer Epidemiology (eds Adami HO., Hunter D., Trichopoulos 
D.) 403–445 (Oxford University Press, 2008).
 5. Walker, L. C. et al. Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant 
carriers. European Journal of Human Genetics. 25, 432–438 (2017).
 6. Kuchenbaecker, K. B. et al. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 
and BRCA2 mutation carriers. Breast cancer research. 16(6), 3416 (2014).
 7. Skol, A. D., Sasaki, M. M. & Onel, K. The genetics of breast cancer risk in the post-genome era: thoughts on study design to move 
past BRCA and towards clinical relevance. Breast Cancer Research. 18(1), 99 (2016).
 8. Li, X. et al. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review. 
Clin Cancer Res. 1;22(15), 3971–81 (2016).
 9. Maas, P. et al. Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States. JAMA 
Oncol 2(10), 1295–1302 (2016).
 10. Castaño-Vinyals, G. et al. Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study 
design. Gac Sanit. 29(4), 308–15 (2015).
 11. Hunter, D. J. et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 
5(12), 977–85 (2005).
 12. Joshi, A. D. et al. Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide 
association studies and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium. Am J Epidemiol 180(10), 
1018–1027 (2014).
 13. Barrdahl, M. et al. Post-GWAS gene-environment interplay in breast cancer: results from the Breast and Prostate Cancer Cohort 
Consortium and a meta-analysis on 79,000 women. Hum Mol Genet 23(19), 5260–5270 (2014).
 14. Reed, E. et al. A guide to genome‐wide association analysis and post‐analytic interrogation. Statistics in medicine 34(28), 3769–3792 (2015).
 15. Solé, X., Guinó, E., Valls, J., Iniesta, R. & Moreno, V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 
22(15), 1928–1929 (2006).
 16. Chatterjee, N. et al. Projecting the performance of risk prediction based on polygenic analyses of genome-wide association studies. 
Nature Genet 45, 400–405 (2013).
 17. Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics 45, 353–361 (2013).
 18. Michailidou, K. et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for 
breast cancer. Nature Genetics 47, 373–380 (2015).
 19. Pencina, M. J., D’Agostino, R. B. Sr., D’Agostino, R. B. J. & Vasan, R. S. Evaluating the added predictive ability of a new marker: from 
area under the ROC curve to reclassification and beyond. Statistics in Medicine 27, 157–172 (2008).
 20. Pencina, M. J., D’Agostino, R. B. Sr. & Steyerberg, E. W. Extensions of net reclassification improvement calculations to measure 
usefulness of new biomarkers. Stat Med 30(1), 11–21, https://doi.org/10.1002/sim.4085 (2011).
 21. Globocan, http://globocan.irac.fr/Pages/online.aspx. Accessed Feb 20 (2017).
 22. Siu, A. L. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 164(4), 
279–96 (2016).
 23. Wong, E. M. et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated 
pathology in early-onset breast cancer. Cancer Prevention Research. 4(1), 23–33 (2011).
 24. Mandelblatt, J. S. et al. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening 
Strategies. Ann Intern Med. 164(4), 215–25, https://doi.org/10.7326/M15-1536 (2016).
 25. Cini, G. et al. Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved 
mutation analysis strategy. BMC medical genetics. 17(1), 11 (2016).
 26. Kurian, A. W. & Ford, J. M. Multigene panel testing in oncology practice: how should we respond? JAMA Oncol. 1(3), 277–8 (2015).
 27. Kurian, A. W. et al. Genetic Testing and Counseling Among Patients with Newly Diagnosed Breast Cancer. JAMA 317(5), 531–534 
(2017).
 28. Costas, L. et al. Hormonal contraception and postmenopausal hormone therapy in Spain: time trends and patterns of use. 
Menopause 22, 1138–46, https://doi.org/10.1097/GME.0000000000000487 (2015).
 29. Rosner, B. & Colditz, G. A. Nurses’ Health Study: Log-incidence mathematical model of breast cancer incidence. JNCI 88, 359–64 
(1996).
 30. Colditz, G. A. & Rosner, B. Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses’ 
Health Study. Am J Epidemiol 152, 950–64 (2000).
Acknowledgements
The study was partially funded by the “Acción Transversal del Cancer” project, approved by the Spanish Council 
of Ministers on the 11th October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, 
PI08/1359, PI09/00773-Cantabria, PI09/01286-León, PI09/01903-Valencia, PI09/02078-Huelva, PI09/01662-
Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, 
PI12/01270, PI12/00715, PI12/00150, PI14/01219), by the Fundación Marqués de Valdecilla (API 10/09), by the 
ICGC International Cancer Genome Consortium CLL (The ICGC CLL-Genome Project is funded by Spanish 
Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and 
Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)), by the Junta de Castilla 
y León (LE22A10-2), by the Consejería de Salud of the Junta de Andalucía (2009-S0143), by the Conselleria 
de Sanitat of the Generalitat Valenciana (AP_061/10), by the Recercaixa (2010ACUP 00310), by the Regional 
Government of the Basque Country, by the European Commission grants FOOD-CT-2006-036224-HIWATE, by 
the Spanish Association Against Cancer (AECC) Scientific Foundation and by the Catalan Government DURSI 
grant 2009SGR1489.
www.nature.com/scientificreports/
8SCIENTIFIC RePoRTS |  (2018) 8:3036  | DOI:10.1038/s41598-018-20832-0
Author Contributions
T.D.S., I.G.A., C.P., M.K., M.P. and J.L. contributed substantially to the conception, design and acquisition of data. 
T.D.S., I.G.A., C.P. and J.L. contributed to the analysis and interpretation of the data. T.D.S., I.G.A., P.R.C. and J.L. 
contributed to devising the draft of the article. The remaining authors (B.P.G., J.M.A., C.G.D., E.A., M.B., J.A.M., 
C.V., R.M.G., V.M., G.C.V., M.E., L.V.M., P.A., A.T., J.B.C., D.S.T., N.A. and P.F.N.) participated in the patients’ 
recruitment, acquisition of data and critical revision of the manuscript. All authors approved the final version to 
be published.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-20832-0.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
